Feb 2024 – Actual Region Covered: Spain, Portugal, United Kingdom, Croatia, Czech Republic & Turkey To stablish the presence of Medical department in Europe Development of the European Strategic Medical plan Identification of EU clinical needs for our Obexelimab trials phase 2/3 of IgG4-Related Disease (IgG4-RD), Worm Autoimmune Haemolytic anaemia (wAIHA), Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) Identifying potential molecule gaps in order to improve the formulation at R&D level. KOL mapping and Principal Investigator management

2016 – Jan 2024 Create global trademark strategy, branding, and artwork design for the whole pipeline. Represent the company at global level by building professional relationships with international KOLs and partners. Perform as member of BIOSIM (Spanish Biosimilars Medicines Association) communication work group. Initiate new business opportunities and liaise with external clients. Manage strategic and digital planning of marketing department and corporate enterprise strategy. Act as global advisor for B2C Business/non-MAH countries on pipeline launches with ad-hoc strategic local. Develop institutional projects and uphold market access. Ensured successful corporate image by serving as head of internal and external positioning. Co-developed strategy for CDMO platform (Contract Development Manufacture Organisation). Collaborated with the US for pre-marketing and launch of Bevacizumab-maly (Alymsys®) in October 2022. Secured European leadership for strategic launch (HQ) of Bevacizumab (Alymsys®) in April 2020. First time company- launched Bevacizumab (Bevax®) in Argentina with record sales in the first six months post-launch in November 2016. Delivered first publication on Future Oncology and Gabi online: Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars in April 2022. https://pubmed.ncbi.nlm.nih.gov/33904318/ Development of the strategic plan and action plan for launch of Bevacizumab (Alymsys®) throughout EU, being mAbxience the marketing authorisation holder (MAH) for the product. March '20.

Focused on patients and associations of patients regarding Human Health Care (HHC) philosophy. Monitored KOLs, such as general neurologists, neurophysiologists, neuropediatricians, and epileptologists. Reported International Brand Director (HQ). Co-marketed with Bial Pharma for Zebinix® (Eslicarbazepine acetate) in Epilepsy Area (CNS). Maintained leadership position in epilepsy market, 2015 and 2016. Relaunched Inovelon® (Rufinamide) for classified rare diseases, Lennox-Gastaut Syndrome, in epilepsy area (CNS). Succeeded in overtaking main competitor (Lacosamide, Vimpat®, UCB) in sales, December 2014.

Managed launch of Effentora® (Buccal fentanyl tablet) for pain unit. Steered KOLs, such as oncologists, radiation oncologists, and pain/palliative care units. Created highly successful projects aimed at doctors and patients. Led exponential growth of Effentora® following termination of co-marketing with Ferrer Pharmaceuticals via single sales network. Re-launched Effentora® after termination of co-marketing agreement with Ferrer Pharma with continuous growth. Launched Bocasil® (Glyceryl Dioleate) in oncology area (OTC) - healthcare product for oral mucositis.